Xi Cheng

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Assays of different aspects of haemostasis – what do they measure?

Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study

Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis

The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients

Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Obesity and Altered Aspirin Pharmacology

Aspirin and Antiplatelet Agent Resistance

The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition

Aspirin resistance

The use of the VerifyNowsystem to monitor antiplatelet therapy: A review of the current evidence

Measuring antiplatelet drug effects in the laboratory

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Aspirin and Antiplatelet Agent Resistance

Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy

Conducting Meta-Analyses inRwith themetaforPackage

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Relation of Aspirin Resistance to Coronary Flow Reserve in Patients Undergoing Elective Percutaneous Coronary Intervention

Low-dose aspirin increases aspirin resistance in patients with coronary artery disease

Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease